Evidence map›Paper›PMID 34076901›Full record

Trial reportJournal of medical virology2021

Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study.

Sherief Abd-Elsalam, Rasha A Noor, Rehab Badawi, Mai Khalaf, Eslam S Esmail, Shaimaa Soliman, Mohamed S Abd El Ghafar, Mohamed Elbahnasawy, Ehab F Moustafa, Sahar M Hassany and 6 more

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of medical virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 13 pooled it
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 13 syntheses or guidelines pooled it, 109 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Ivermectin for preventing and treating COVID-19.The Cochrane database of systematic reviews · 2022
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Is Ivermectin Effective in Treating COVID-19?Frontiers in pharmacology · 2022
    Pooled it
  11. Pooled it
  12. Characteristics of published/registered clinical trials on COVID-19 treatment: A systematic review.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2021
    Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Sherief Abd-ElsalamDepartment of Tropical Medicine and Infectious diseases, Faculty of Medicine, Tanta University, Tanta, Egypt.ORCID http://orcid.org/0000-0003-4366-2218
Rasha A NoorDepartment of Internal Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt.
Rehab BadawiDepartment of Tropical Medicine and Infectious diseases, Faculty of Medicine, Tanta University, Tanta, Egypt.
Mai KhalafDepartment of Tropical Medicine and Infectious diseases, Faculty of Medicine, Tanta University, Tanta, Egypt.
Eslam S EsmailDepartment of Tropical Medicine and Infectious diseases, Faculty of Medicine, Tanta University, Tanta, Egypt.
Shaimaa SolimanDepartment of Public health and Community Medicine, Faculty of Medicine, Menoufia University, Menoufia, Egypt.
Mohamed S Abd El GhafarDepartment of Anesthesia, Surgical Intensive Care, and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt.
Mohamed ElbahnasawyDepartment of Emergency Medicine and traumatology, Faculty of Medicine, Tanta University, Tanta, Egypt.ORCID http://orcid.org/0000-0001-8706-4389
Ehab F MoustafaDepartment of Tropical Medicine and Gastroenterology, Faculty of Medicine, Assiut University, Assiut, Egypt.
Sahar M HassanyDepartment of Tropical Medicine and Gastroenterology, Faculty of Medicine, Assiut University, Assiut, Egypt.
Mohammed A MedhatDepartment of Tropical Medicine and Gastroenterology, Faculty of Medicine, Assiut University, Assiut, Egypt.
Haidi Karam-Allah RamadanDepartment of Tropical Medicine and Gastroenterology, Faculty of Medicine, Assiut University, Assiut, Egypt.
Maii A S EldeenDepartment of Microbiology and Immunology, Tanta University, Tanta, Egypt.
Mohamed AlboraieDepartment of Internal Medicine, Al-Azhar University, Cairo, Egypt.
Ahmed CordieDepartment of Endemic Medicine, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt.
Gamal EsmatDepartment of Endemic Medicine, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt.
Tanta University · EGAssiut University · EGCairo University · EGAl-Azhar University · EGMenoufia University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Researchers around the world are working at record speed to find the best ways to treat and prevent coronavirus disease 2019 (COVID-19). This study aimed to evaluate the efficacy of ivermectin for the treatment of hospitalized mild to moderate COVID-19 infected patients. This was a randomized open-label controlled study that included 164 patients with COVID-19. Patients were randomized into two groups where Group 1 (Ivermectin group) included patients who received ivermectin 12 mg once daily for 3 days with standard care and Group 2 (control group) included patients who received standard protocol of treatment alone for 14 days. The main outcomes were mortality, the length of hospital stay, and the need for mechanical ventilation. All patients were followed up for 1 month. Overall, 82 individuals were randomized to receive ivermectin plus standard of care and 82 to receive standard of care alone. Patients in the ivermectin group had a shorter length of hospital stay (8.82 ± 4.94 days) than the control group (10.97 ± 5.28 days), but this was not statistically significant (p = 0.085). Three patients (3.7%) in each group required mechanical ventilation (p = 1.00). The death rate was three patients in the ivermectin group (3.7%) versus four patients (4.9%) in the control group without any significant difference between the two groups (p = 1.00). Although there was no statistically significant difference in any endpoints by ivermectin doses (12 mg/day for 3 days); there was an observed trend to reducing hospital stay in the ivermectin-treated group.

Indexed as

COVID-19 Drug TreatmentAdultAgedAntiviral AgentsCOVID-19EgyptFemaleHumansIvermectinLength of StayMaleMiddle AgedRespiration, ArtificialSARS-CoV-2Treatment OutcomeAntiviral AgentsIvermectinchloroquineCOVID-19ivermectinmortalitytreatment

Identifiers

PMID34076901
PMCPMC8242425
OpenAlexW3164512669

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.